This is even more important when considering that this strategy may allow the improvement of the outcome of anti-cancer therapies even against cancers carrying mutations in p53-encoding gene, which are known to be highly resistant to most cytotoxic treatments [49]. The gene discussed is TP53; the disease is cancer.